Good morning and welcome to Wednesday's report - the Agenda is now complete. It's an awfully long list to digest but the good news is that there are hardly any profit warnings!
Companies Reporting
Name (Mkt Cap) | RNS | Summary | Our view (Author) |
---|---|---|---|
GSK (LON:GSK) (£58.9bn) | Sales +2%. Op profit +50% to £2.2bn helped by accounting methods. Guidance unchanged. | ||
Barclays (LON:BARC) (£42.6bn) | Ahead of expectations, PBT £2.7bn vs. £2.5bn forecast (Reuters). | ||
HALEON (LON:HLN) (£34.0bn) | Reiterates FY 2025 guidance. Organic revenue growth 4-6%, organic op profit ahead of this. | ||
Glencore (LON:GLEN) (£31.8bn) | Production guidance unchanged except for 5% reduction to energy coal’s range. | ||
Prudential (LON:PRU) (£21.0bn) | Q1 new business profit +12% to $608m, consistent with guidance for FY growth of more than 10%. | ||
Coca Cola HBC AG (LON:CCH) (£13.6bn) | Organic volume +1.8%, organic revenue +8.7%. Reiterating financial guidance for the year. | ||
Smith & Nephew (LON:SN.) (£8.7bn) | Underlying revenue growth 3.1%. Full year guidance unchanged. Includes $15-20m tariff impact. | ||
Melrose Industries (LON:MRO) (£5.5bn) | Q1 in line with expectations. Guidance unchanged but excludes any tariff impact. | ||
Taylor Wimpey (LON:TW.) (£4.2bn) | Full year guidance reiterated: operating profit of £444m. Small reduction in final dividend. Order book at 27 Apr was £2,335m, versus £2,093m last year. H1 25 margin expected to be lower than H1 24 due to the return of build cost inflation. | AMBER (Roland) [no section below] | |
Aberdeen (LON:ABDN) (£2.7bn) | Q1 net outflows £5.2bn. Inflows at interactive investor. Still on track to meet FY 2026 growth targets. | GREEN (Graham) I am AMBER/GREEN on some fund managers now but Aberdeen strikes me as a likely winner in the sector… |